Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Targeted Temperature Management in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy: A Case Report.

Created on 01 Oct 2026

Authors

Surabhi Sandill, Nishkarsh Gupta, Alisha Chachra, Mukurdipi Ray

Published in

A&A practice. Volume 20. Issue 9. Pages e02280. Sep 01, 2026. Epub Sep 08, 2026.

Abstract

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) treats peritoneal carcinomatosis by circulating heated (42 °C) chemotherapeutic solutions intra-abdominally, but risks severe systemic hyperthermia due to inconsistent temperature control protocols. Conventional methods like cooled fluids, ice packs, and cooling devices often prove inadequate, with slow response times and limited precision during open surgery. This case underscores the need for vigilance regarding perioperative hyperthermia during HIPEC and suggests employing targeted temperature management (TTM) with a 33 °C target, which limited core temperature rise from 36.1 °C to 37.4 °C (Δ1.3 °C) over 90 minutes of HIPEC-lower than fluctuations in non-TTM cases. TTM's real-time feedback enables rapid, automated shifts from warming (CRS phase) to cooling (HIPEC phase), reducing reliance on multiple adjuncts and minimizing thermal deviations. This approach enhances patient safety, optimizes therapeutic delivery, and may improve outcomes in CRS-HIPEC.

PMID:
42814392
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement